Repligen Corporation (NASDAQ:RGEN) saw a downside of -3.14% to close Friday at $157.80 after subtracting -$5.12 on the day. The 5-day average trading volume is 471,580 shares of the company’s common stock. It has gained $176.52 in the past week and touched a new high 2 times within the past 5 days. An average of 549,975 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 624,410.
RGEN’s 1-month performance is 0.17% or $1.21 on its low of $153.36 reached on 07/21/23. The company’s shares have touched a 52-week low of $134.64 and high of $249.74, with the stock’s rally to the 52-week high happening on 02/16/23. YTD, RGEN has lost -6.80% or -$11.51 and has reached a new high 8 times. However, the current price is down -36.81% from the 52-week high price.
Insider Transactions
RGEN stock investors last saw insider trading activity on May 08.Snodgres Jon (Chief Financial Officer) most recently sold 5,647 shares at $200.00 per share on Feb 16. This transaction cost the insider $1,129,400. Chief Executive Officer, Hunt Anthony, sold 25,000 shares at a price of $200.00 on Nov 11. Then, on Sep 09, Director DAWES KAREN A sold 775 shares at a price of $227.17 per share. This transaction amounted to $176,057.
Valuation Metrics
RGEN stock has a beta of 1.01. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.46 while the price-to-book (PB) in the most recent quarter is 4.46, with the price to cash flow ratio at 94.43.
Repligen Corporation’s quick ratio for the period ended June 29 was 2.00, with the current ratio over the same period at 2.70. In terms of profitability, the gross margin trailing 12 months is 53.60%. The trailing 12-month EBITDA margin is 31.96% while for the period ending June 29, Repligen Corporation’s operating margin was 20.90%. The firm’s gross profit as reported stood at $455.71 million against revenue of $801.54 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -148.55% to $20.06 million, while revenue of $28.83 million was -43.72% off the previous quarter. Analysts expected RGEN to announce $0.47 per share in earnings in its latest quarter, but it posted $0.53, representing a 12.80% surprise. EBITDA for the quarter stood at more than $35.84 million. RGEN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 578.08 million, with total debt at $422.85 million. Shareholders hold equity totaling $55.76 million.
Let’s look briefly at Repligen Corporation (RGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 29.33% to suggest the stock is trending oversold, with historical volatility in this time period at 25.35%.
The stock’s 5-day moving average is $167.31, reflecting a -8.37% or -$14.41 change from its current price. RGEN is currently trading -10.00% above its 20-day SMA, -5.54% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -8.69% and SMA200 by-13.53%.
Stochastic %K and %D was 12.22% and 31.14% and the average true range (ATR) pointed at 6.29. The RSI (14) points at 38.99%, while the 14-day stochastic is at 2.41% with the period’s ATR at 6.47. The stock’s 9-day MACD Oscillator is pointing at -6.76 and -6.94 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Repligen Corporation (NASDAQ: RGEN), Wells Fargo launched coverage with an Overweight rating. Analysts offering their rating for RGEN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RGEN as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 11 have offered a “buy” rating.
What is RGEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $165.00 and a high of $240.00, with their median price target at $200.00. Looking at these predictions, the average price target given by analysts is for Repligen Corporation (RGEN) stock is $197.92.
